+ .23 on triple volume. Its been a long haul. Like IMGN, got stuck with token royalties from Roche. Still got to believe one of these ships has to come in one day. I guess. GLTAL's
Thanks, Bioimmuno, old buddy. Feuerstein reports a big biotech fund liquidating. Question is whether this presents an opportunity for buying, or whether it ignites a firestorm of selling during this stock fire season of May.
Do you know where the floor is currently for a good buy-in price? Something, hopefully not stubborness or ego, compel me to want to buy more of this POS. Sincere thanks in advance to my respected fellows.
Everything changes. The real surprise to most of us was: 1) the low royalty rate, and 2) IMGN's public shift of direction towards a more independent drug developer. In retrospect, both were possible to envision, noting Bioimmuno's point about the cost of drug development and IMGN's then status as early stage co., and management's desire to now claim a bigger piece of its pie now that the tech has been proven. Fool just changed its view as things became more obvious.
Please don't remind me about SGEN. We just have to get used to the idea that the market likes what the market likes, and that is just the way it is, versus how it "should" be.
I have lost big money in stocks before, my mistake, take it like a man. But this was a massive set-up by Raj, who profited handsomely while misleading investors using his insider information and public platform. This time its different, and so I contacted the first law firm doing its preliminary investigation offering my full cooperation. Raj and his cronies need to cough up their ill-gotten riches, and pay the price for this fraud on shareholders.
You are right, rvfirst. I should have trusted my instincts, when Raj sold shares off in the 12's, while telling us that this was worth so much more. Then we hear he pays himself more than just about any CEO around. Then he seems to take it so personally, that there are so many shorts, doth protesting too much. I am learning to ignore what biotech CEOs say, especially this con artist. Looks like the crows and circling vulture shorts were right, they usually smell a desperado first. And me, I am out a whole bunch of money. I think this con was short-sited, too, because no Nobody will believe this guy, not just AF. Investors won't trust him anymore, the self-serving POS.
From living and breathing this stock on the long side for Many years, I am getting the feeling that the shorts are finally getting exhausted, or least weary of picking on SPPI. They have beaten this pinata too long, and are drifting on to fatter targets. I am calling a bottom on this stock, finally, or my name isn't Biobottom. As reflected by the low PE in the face of Spectrum's long and strong record of growth and execution, the stock is way undervalued, and has been held down by sentiment and self-fulfilling pile-ons by shorts, nothing fundamental. IMO, that is coming to an end now, as these crows and vultures move on.
What froth? The price action here is almost as pathetic as Spectrum's (SPPI). Oh, that's right, half of SPPI's float is short. Nevermind. Glad for holding CLDX and ARIA: +280%. That's what IMGN should be doing. Speaking of oldtimers, where is that miscreant AMP?
Desert Dweller, I appreciate your post. I wish you luck, or rather reward for your patience and efforts. I am a relative newbie to Curis, so thanks for the welcome and tip re the Google board. Its a relief to find people that speak sensibly re CRIS, although Hamsters deserves honorable mention, there and on this IMGN board. Congrats on your SGEN pick. I think IMGN will turn out even better once the launch rolls out. IMGN management, which I was critical of, actually now strikes me as pretty savvy, and I think is positioning this company for the big time by building up a war chest while times are good, and betting on their own drug(s). I think that is really the only way to go big like Amgen, Biogen, Genentech, and now ONXX, which I remember all as little start-up companies. If anything, Immunogen's technology has broader and more valuable application than any of these.
Hamsters, you turned me on to CRIS a couple of years ago. Yes, related to IMGN as precocious sibling, with common Roche stepfather. Posters here on IMGN board mostly excellent, CRIS board is a worthless madhouse. BTW, thx for lead to 901 presentation slides on IMGN website, but as a non-scientist, waay over my head, although I puzzled over them for a while. IMO, CRIS will get bought out before IMGN, which is hampered by the "why buy the cow when you get the milk for free (or, rather at 3-5%)" theory.
Muchas Gracias, mi Amigo Hamsters. Now, if we could only get CRIS off the ground! CLDX working out nicely, another conjugate in the works. TAP is where its at! BTW, having a nice day thanks to Cramer. AF must not be amused!
Thanks, Bioimmuno, you are a most valuable contributor to this board. I will do some further due diligence on 901 and try to contribute back. W/ regard to partnered agents, I sure hope they have better royalty deals than TDM-1. That was a real wet blanket when it was finally disclosed to us retail investors and the larger marketplace. Although you would have to think that the institutional investors who bought in at $16 had to know.
Bioimmuno, we always see eye to eye, as with Hamsters, but why are you not so keen on 901? If memory serves, this drug excited me many years ago, and now seems to be rising to the surface. If not this wholly owned drug, what else is good for a follow thru to TDM1? Thx in advance. Biobottom
You got that right, Bioimmuno. This self-serving management bugs me too. Maybe the far smarter and skilled Roche management (CEO of the year in some survey) really ought to just buy IMGN out, golden parachutes and all, and have done with it. Still, free options are probable, but more dilution now, no way.